Choroidal Neovascularization in Pathologic Myopia: Intravitreal Ranibizumab Versus Bevacizumab—A Randomized Controlled Trial

Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization

“…[8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25] Although the short-term results have demonstrated significant visual improvement following anti-VEGF therapy, the longer term visual outcomes appeared more variable. 14,[26][27][28] In addition, many previous studies have included both treatment naïve cases and previously treated eyes, as well as subfoveal and non-subfoveal CNV in the series, making comparison of results more difficult.…”

“…5,6 However, the long-term outcome of PDT is not favourable as patients generally had no improvement in mean visual acuity following treatment and the beneficial effect of PDT in preventing visual loss was no longer significant at 2 years. 6,7 In the past few years, various studies have demonstrated the short-term efficacy of intravitreal antivascular endothelial growth factor (VEGF) agents in treating myopic CNV, including both bevacizumab [8][9][10][11][12][13][14][15][16][17][18] and ranibizumab. [18][19][20][21][22][23][24][25] Most of the studies have demonstrated significant mean visual improvement after anti-VEGF therapy and the beneficial effects were maintained at 12 months.…”

Antiangiogenic Therapy for Ischemic Retinopathies

“…Those findings have led toward wider use of anti-VEGF agent in these disorders (Ikuno et al 2009;Gharbiya et al 2010). Other studies have shown potential benefit of bevacizumab in treatment of CNVM related to angioid streaks and ocular inflammatory diseases (Mansour et al 2009;Wiegand et al 2009).…”

Cellular level characterization of capillary regression in inflammatory angiogenesis using an in vivo corneal model

“…Steroids have long been used to promote the regression of undesirable neovessels and are well known for their anti-inflammatory and antiangiogenic effect [15][16][17]. More recently, bevacizumab, a monoclonal VEGF-A antibody approved for the treatment of metastatic colorectal cancer, has been widely used off-label to successfully induce regression in eye-related angiogenesis in cases of choroidal, retinal and corneal neovascularization in patients [18][19][20][21][22][23][24].…”